Xanthohumol and 8-prenylnaringenin ameliorate diabetic-related metabolic dysfunctions in mice

Journal of Nutritional Biochemistry

Volumn 45, Issue , 2017, Pages 39-47

  Costa, Raquel ^a,b   Rodrigues, Ilda ^a   Guardão, Luísa ^a   Rocha Rodrigues, Sílvia ^c   Silva, Carolina ^a,b   Magalhães, José ^c   Ferreira de Almeida, Manuel ^d   Negrão, Rita ^a,b   Soares, Raquel ^a,b  

^a University of Porto   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

Liver; Metabolism; Polyphenols; Skeletal muscle; Type 2 diabetes mellitus

Indexed keywords

8 PRENYLNARINGENIN; ALCOHOL; ALKALINE PHOSPHATASE; CHOLESTEROL; GLUCOSE; GLUCOSE TRANSPORTER 4; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIPID; LOW DENSITY LIPOPROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR 1; XANTHOHUMOL; 8-PRENYLNARINGENIN; ACETYL COENZYME A CARBOXYLASE; FAS PROTEIN, MOUSE; FLAVANONE DERIVATIVE; FLAVONOID; PROPIOPHENONE DERIVATIVE; SREBF2 PROTEIN, MOUSE; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 6;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIPID BLOOD LEVEL; LIPID DIET; LIPID TRANSPORT; MALE; METABOLIC DISORDER; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PROTEIN EXPRESSION; QUANTITATIVE INSULIN SENSITIVITY CHECK INDEX; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; ANIMAL; BLOOD; C57BL MOUSE; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GLYCOLYSIS; METABOLISM;

ACETYL-COA CARBOXYLASE; ANIMALS; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; FAS RECEPTOR; FLAVANONES; FLAVONOIDS; GLYCOLYSIS; INSULIN RESISTANCE; LIPIDS; MALE; MICE, INBRED C57BL; PROPIOPHENONES; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 85018477319     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2017.03.006     Document Type: Article

References (42)

1. [1] Shaw, J.E., Sicree, R.A., Zimmet, P.Z., Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87 (2010), 4–14.
2. [2] Tiwari, P., Recent trends in therapeutic approaches for diabetes management: a comprehensive update. J Diabetes Res, 2015, 2015, 340838.
3. [3] van Dam, R.M., Naidoo, N., Landberg, R., Dietary flavonoids and the development of type 2 diabetes and cardiovascular diseases: review of recent findings. Curr Opin Lipidol 24 (2013), 25–33.
4. [4] Rains, T.M., Agarwal, S., Maki, K.C., Antiobesity effects of green tea catechins: a mechanistic review. J Nutr Biochem 22 (2011), 1–7.
5. [5] Gerhauser, C., Frank, N., Xanthohumol, a new all-rounder?. Mol Nutr Food Res 49 (2005), 821–823.
6. [6] Stevens, J.F., Page, J.E., Xanthohumol and related prenylflavonoids from hops and beer: to your good health!. Phytochemistry 65 (2004), 1317–1330.
7. [7] Zanoli, P., Zavatti, M., Pharmacognostic and pharmacological profile of Humulus lupulus L. J Ethnopharmacol 116 (2008), 383–396.
8. [8] Miranda, C.L., Elias, V.D., Hay, J.J., Choi, J., Reed, R.L., Stevens, J.F., Xanthohumol improves dysfunctional glucose and lipid metabolism in diet-induced obese C57BL/6J mice. Arch Biochem Biophys 599 (2016), 22–30.
9. [9] Hardie, D.G., AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes 62 (2013), 2164–2172.
10. [10] Ramesh, M., Vepuri, S.B., Oosthuizen, F., Soliman, M.E., Adenosine monophosphate-activated protein kinase (AMPK) as a diverse therapeutic target: a computational perspective. Appl Biochem Biotechnol 178 (2016), 810–830.
11. [11] Goldstein, J.L., DeBose-Boyd, R.A., Brown, M.S., Protein sensors for membrane sterols. Cell 124 (2006), 35–46.
12. [12] Lopez, J.M., Bennett, M.K., Sanchez, H.B., Rosenfeld, J.M., Osborne, T.F., Sterol regulation of acetyl coenzyme a carboxylase: a mechanism for coordinate control of cellular lipid. Proc Natl Acad Sci U S A 93 (1996), 1049–1053.
13. [13] Magana, M.M., Osborne, T.F., Two tandem binding sites for sterol regulatory element binding proteins are required for sterol regulation of fatty-acid synthase promoter. J Biol Chem 271 (1996), 32689–32694.
14. [14] Sato, R., Sterol metabolism and SREBP activation. Arch Biochem Biophys 501 (2010), 177–181.
15. [15] Xiao, X., Song, B.L., SREBP: a novel therapeutic target. Acta Biochim Biophys Sin (Shanghai) 45 (2013), 2–10.
16. [16] Abu-Elheiga, L., Matzuk, M.M., Kordari, P., Oh, W., Shaikenov, T., Gu, Z., et al. Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal. Proc Natl Acad Sci U S A 102 (2005), 12011–12016.
17. [17] Horton, J.D., Goldstein, J.L., Brown, M.S., SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109 (2002), 1125–1131.
18. [18] Choi, Y.J., Suh, H.R., Yoon, Y., Lee, K.J., Kim, D.G., Kim, S., et al. Protective effect of resveratrol derivatives on high-fat diet induced fatty liver by activating AMP-activated protein kinase. Arch Pharm Res 37 (2014), 1169–1176.
19. [19] Li, Y., Xu, S., Mihaylova, M.M., Zheng, B., Hou, X., Jiang, B., et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 13 (2011), 376–388.
20. [20] Goldberg, I.J., Eckel, R.H., Abumrad, N.A., Regulation of fatty acid uptake into tissues: lipoprotein lipase- and CD36-mediated pathways. J Lipid Res(Suppl. 50), 2009, S86–S90.
21. [21] Su, X., Abumrad, N.A., Cellular fatty acid uptake: a pathway under construction. Trends Endocrinol Metab 20 (2009), 72–77.
22. [22] Kelley, D.E., Goodpaster, B.H., Skeletal muscle triglyceride. An aspect of regional adiposity and insulin resistance. Diabetes Care 24 (2001), 933–941.
23. [23] Aoun, M., Michel, F., Fouret, G., Schlernitzauer, A., Ollendorff, V., Wrutniak-Cabello, C., et al. A grape polyphenol extract modulates muscle membrane fatty acid composition and lipid metabolism in high-fat–high-sucrose diet-fed rats. Br J Nutr 106 (2011), 491–501.
24. [24] Hagberg, C.E., Falkevall, A., Wang, X., Larsson, E., Huusko, J., Nilsson, I., et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 464 (2010), 917–921.
25. [25] Hagberg, C.E., Mehlem, A., Falkevall, A., Muhl, L., Fam, B.C., Ortsater, H., et al. Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature 490 (2012), 426–430.
26. [26] Klip, A., The many ways to regulate glucose transporter 4. Appl Physiol Nutr Metab 34 (2009), 481–487.
27. [27] Domenech, E., Maestre, C., Esteban-Martinez, L., Partida, D., Pascual, R., Fernandez-Miranda, G., et al. AMPK and PFKFB3 mediate glycolysis and survival in response to mitophagy during mitotic arrest. Nat Cell Biol 17 (2015), 1304–1316.
28. [28] Trefely, S., Khoo, P.S., Krycer, J.R., Chaudhuri, R., Fazakerley, D.J., Parker, B.L., et al. Kinome screen identifies PFKFB3 and glucose metabolism as important regulators of the insulin/insulin-like growth factor (IGF)-1 signaling pathway. J Biol Chem 290 (2015), 25834–25846.
29. [29] Zierau, O., Gester, S., Schwab, P., Metz, P., Kolba, S., Wulf, M., et al. Estrogenic activity of the phytoestrogens naringenin, 6-(1,1-dimethylallyl)naringenin and 8-prenylnaringenin. Planta Med 68 (2002), 449–451.
30. [30] Blake, R., Trounce, I.A., Mitochondrial dysfunction and complications associated with diabetes. Biochim Biophys Acta 2014 (1840), 1404–1412.
31. [31] Lee, S., Muniyappa, R., Yan, X., Chen, H., Yue, L.Q., Hong, E.G., et al. Comparison between surrogate indexes of insulin sensitivity and resistance and hyperinsulinemic euglycemic clamp estimates in mice. Am J Physiol Endocrinol Metab 294 (2008), E261–E270.
32. [32] Costa, R., Negrao, R., Valente, I., Castela, A., Duarte, D., Guardao, L., et al. Xanthohumol modulates inflammation, oxidative stress, and angiogenesis in type 1 diabetic rat skin wound healing. J Nat Prod 76 (2013), 2047–2053.
33. [33] Negrao, R., Costa, R., Duarte, D., Taveira Gomes, T., Mendanha, M., Moura, L., et al. Angiogenesis and inflammation signaling are targets of beer polyphenols on vascular cells. J Cell Biochem 111 (2010), 1270–1279.
34. [34] Miyata, S., Inoue, J., Shimizu, M., Sato, R., Xanthohumol improves diet-induced obesity and fatty liver by suppressing sterol regulatory element-binding protein (SREBP) activation. J Biol Chem 290 (2015), 20565–20579.
35. [35] Grassi, D., Desideri, G., Mai, F., Martella, L., De Feo, M., Soddu, D., et al. Cocoa, glucose tolerance, and insulin signaling: cardiometabolic protection. J Agric Food Chem 63 (2015), 9919–9926.
36. [36] Yui, K., Kiyofuji, A., Osada, K., Effects of xanthohumol-rich extract from the hop on fatty acid metabolism in rats fed a high-fat diet. J Oleo Sci 63 (2014), 159–168.
37. [37] Guo, S., Yao, Q., Ke, Z., Chen, H., Wu, J., Liu, C., Resveratrol attenuates high glucose-induced oxidative stress and cardiomyocyte apoptosis through AMPK. Mol Cell Endocrinol 412 (2015), 85–94.
38. [38] Sears, B., Ricordi, C., Role of fatty acids and polyphenols in inflammatory gene transcription and their impact on obesity, metabolic syndrome and diabetes. Eur Rev Med Pharmacol Sci 16 (2012), 1137–1154.
39. [39] Miquilena-Colina, M.E., Lima-Cabello, E., Sanchez-Campos, S., Garcia-Mediavilla, M.V., Fernandez-Bermejo, M., Lozano-Rodriguez, T., et al. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut 60 (2011), 1394–1402.
40. [40] Koonen, D.P., Jacobs, R.L., Febbraio, M., Young, M.E., Soltys, C.L., Ong, H., et al. Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes 56 (2007), 2863–2871.
41. [41] Carmeliet, P., Wong, B.W., De Bock, K., Treating diabetes by blocking a vascular growth factor. Cell Metab 16 (2012), 553–555.
42. [42] Cryer, P.E., Minireview: glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology 153 (2012), 1039–1048.